- Home
- KLRS vs PAYS Comparison
KLRS vs PAYS Comparison
Compare KLRS & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- PAYS
- Stock Information
- Founded
- KLRS 2019
- PAYS 2001
- Country
- KLRS United States
- PAYS United States
- Employees
- KLRS N/A
- PAYS N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- PAYS Business Services
- Sector
- KLRS Health Care
- PAYS Consumer Discretionary
- Exchange
- KLRS Nasdaq
- PAYS Nasdaq
- Market Cap
- KLRS 129.0M
- PAYS 125.2M
- IPO Year
- KLRS N/A
- PAYS 1998
- Fundamental
- Price
- KLRS $2.61
- PAYS $7.66
- Analyst Decision
- KLRS Buy
- PAYS Strong Buy
- Analyst Count
- KLRS 1
- PAYS 4
- Target Price
- KLRS N/A
- PAYS $7.06
- AVG Volume (30 Days)
- KLRS 38.9K
- PAYS 1.1M
- Earning Date
- KLRS 08-15-2025
- PAYS 08-05-2025
- Dividend Yield
- KLRS N/A
- PAYS N/A
- EPS Growth
- KLRS N/A
- PAYS N/A
- EPS
- KLRS N/A
- PAYS 0.11
- Revenue
- KLRS N/A
- PAYS $63,792,627.00
- Revenue This Year
- KLRS N/A
- PAYS $30.03
- Revenue Next Year
- KLRS N/A
- PAYS $20.14
- P/E Ratio
- KLRS N/A
- PAYS $69.87
- Revenue Growth
- KLRS N/A
- PAYS 26.77
- 52 Week Low
- KLRS $2.28
- PAYS $1.80
- 52 Week High
- KLRS $24.15
- PAYS $8.57
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- PAYS 67.52
- Support Level
- KLRS N/A
- PAYS $7.44
- Resistance Level
- KLRS N/A
- PAYS $8.57
- Average True Range (ATR)
- KLRS 0.00
- PAYS 0.53
- MACD
- KLRS 0.00
- PAYS -0.02
- Stochastic Oscillator
- KLRS 0.00
- PAYS 63.01
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.